2-Chloro-6-ethylamino-isonicotinic acid | 56835-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Chloro-6-ethylamino-isonicotinic acid
• 英文别名: 2-Chloro-6-(ethylamino)pyridine-4-carboxylic acid
• CAS: 56835-93-9
• 化学式: C₈H₉ClN₂O₂
• 分子量: 200.625
• InChiKey: DBZHYOIHQWJJJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE RÉCEPTEUR DE SPHINGOSINE 1-PHOSPHATE
  申请人：SWENSON ROLF ERIC

  公开号：WO2014158302A1

  公开（公告）日：2014-10-02

  The present invention relates to sphingosine-1 -phosphate (S1 P) receptors and compounds of the general formula (1), that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1 -phosphate receptor 2 (S1 P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1 P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1 P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

  本发明涉及鞘氨醇-1-磷酸（S1P）受体和一般式（1）的化合物，这些化合物在与这些受体相关的疾病的治疗和预防中是有用的。更具体地，本发明涉及合成和使用鞘氨醇-1-磷酸受体2（S1P2）拮抗剂，这些拮抗剂在癌症、动脉粥样硬化、糖尿病视网膜病变和其他炎症性疾病的治疗中是有用的。这些炎症性疾病中可以用这些S1P2拮抗剂治疗的包括以纤维化为特征的疾病，如慢性肺病、慢性肾脏和肝脏疾病、慢性心脏病，以及硬化/硬皮病等皮肤病。S1P2拮抗剂还可用于治疗多形性胶质母细胞瘤（脑癌）、儿童神经母细胞瘤和其他癌症。
• NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS
  申请人：Arroyo BioSciences L.L.C.

  公开号：EP2831072B1

  公开（公告）日：2017-04-19
• [EN] NOVEL SPHINGOSINE 1-PHOSPHATE RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DES RÉCEPTEURS DE LA SPHINGOSINE 1-PHOSPHATE
  申请人：SWENSON ROLF E

  公开号：WO2013148460A1

  公开（公告）日：2013-10-03

  The present invention comprises sphingosine-1 -phosphate receptor 2 (S1 P2 ) antagonists of the formula: (I) wherein R1 is -CH2CH=CH2, -CH3, or -CH2CH2CH2OH, R2 is -H, -CH2C02H, -CH2CH2OH, -CH2CH2CH2OH, -CH2CONH2, or -CH2C02Et and R3 is 4- substituted-2,6-dichloropyridine, 4-substituted 2-chloro-6-hydroxyethyl pyridine, 4-substituted-2-chloro-6-hydroxypropyl pyridine, 4-substituted-2-(aminoethyl)-6- chloro pyridine, 4-substituted-2-(aminoethylmethyl)-6-chloro pyridine or 5- substituted-2,3-dichloro thiophene. Pharmaceutical compositions comprising the sphingosine-1 -phosphate S1 P2 receptor 2 antagonist receptors are also disclosed as being useful in the treatment of neoplastic ocular disorders and blindness as well as fibrotic lung, kidney, liver and skin diseases.